CXCL10 and melanoma: Treatment with guadecitabine or DAC vs. AZA induced the mRNA expression of CXCL10 in 38.5% (5/13) and 30.7% (4/13) vs. 15.4% (2/13) chemokine-negative melanoma cell lines, with no differences in the mean values of induced CXCL10 molecules among investigated DHAs (Supplementary Table 15).